JP6924907B2 - Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 - Google Patents
Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 Download PDFInfo
- Publication number
- JP6924907B2 JP6924907B2 JP2020546259A JP2020546259A JP6924907B2 JP 6924907 B2 JP6924907 B2 JP 6924907B2 JP 2020546259 A JP2020546259 A JP 2020546259A JP 2020546259 A JP2020546259 A JP 2020546259A JP 6924907 B2 JP6924907 B2 JP 6924907B2
- Authority
- JP
- Japan
- Prior art keywords
- pmvk
- protein
- expression level
- cancer
- radiotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/04—Phosphotransferases with a phosphate group as acceptor (2.7.4)
- C12Y207/04002—Phosphomevalonate kinase (2.7.4.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/91235—Phosphotransferases in general with a phosphate group as acceptor (2.7.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Description
Claims (10)
- ホスホメバロン酸キナーゼ(PMVK)タンパク質またはそれをコーディングする遺伝子を有効成分として含む放射線抵抗性肺癌または膵臓癌診断用バイオマーカー組成物。
- PMVKの発現レベルを測定することができる製剤を有効成分として含む放射線抵抗性肺癌または膵臓癌診断用組成物。
- 前記PMVKの発現レベルを測定することができる製剤は、前記PMVK遺伝子に特異的に結合するプライマーまたはプローブ、または前記PMVKタンパク質に特異的に結合する抗体、ペプチド、アプタマーまたは化合物であることを特徴とする請求項2に記載の放射線抵抗性肺癌または膵臓癌診断用組成物。
- 請求項2または3に記載の組成物を含む放射線抵抗性肺癌または膵臓癌診断用キット。
- ホスホメバロン酸キナーゼ(PMVK)タンパク質またはそれをコーディングする遺伝子を有効成分として含む肺癌または膵臓癌患者の放射線治療予後予測用バイオマーカー組成物。
- PMVKの発現レベルを測定することができる製剤を有効成分として含む肺癌または膵臓癌患者の放射線治療予後予測用組成物。
- 前記PMVKの発現レベルを測定することができる製剤は、前記PMVK遺伝子に特異的に結合するプライマーまたはプローブ、または前記PMVKタンパク質に特異的に結合する抗体、ペプチド、アプタマーまたは化合物であることを特徴とする請求項6に記載の肺癌または膵臓癌患者の放射線治療予後予測用組成物。
- 請求項6または7に記載の組成物を含む肺癌または膵臓癌患者の放射線治療予後予測用キット。
- (1)肺癌または膵臓癌患者から分離された試料からPMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルを測定する段階と、
(2)前記PMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルを対照群試料と比較する段階と、
(3)前記PMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルが対照群試料よりも高い場合、放射線抵抗性肺癌または膵臓癌であると判断する段階と、
を含む放射線抵抗性肺癌または膵臓癌診断に必要な情報を提供する方法。 - (1)肺癌または膵臓癌患者から分離された試料からPMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルを測定する段階と、
(2)前記PMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルを対照群試料と比較する段階と、
(3)前記PMVK遺伝子のmRNA発現レベルまたはPMVKタンパク質の発現レベルが対照群試料よりも高い場合、放射線治療予後が良くないと判断する段階と、
を含む肺癌または膵臓癌患者の放射線治療予後予測に必要な情報を提供する方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021111826A JP7167263B2 (ja) | 2017-11-22 | 2021-07-05 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170156320 | 2017-11-22 | ||
KR10-2017-0156320 | 2017-11-22 | ||
KR10-2018-0143493 | 2018-11-20 | ||
KR1020180143493A KR102141997B1 (ko) | 2017-11-22 | 2018-11-20 | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 |
PCT/KR2018/014363 WO2019103456A2 (ko) | 2017-11-22 | 2018-11-21 | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021111826A Division JP7167263B2 (ja) | 2017-11-22 | 2021-07-05 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021504726A JP2021504726A (ja) | 2021-02-15 |
JP6924907B2 true JP6924907B2 (ja) | 2021-08-25 |
Family
ID=66675714
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020546259A Active JP6924907B2 (ja) | 2017-11-22 | 2018-11-21 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
JP2021111826A Active JP7167263B2 (ja) | 2017-11-22 | 2021-07-05 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021111826A Active JP7167263B2 (ja) | 2017-11-22 | 2021-07-05 | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11674184B2 (ja) |
EP (1) | EP3715475A4 (ja) |
JP (2) | JP6924907B2 (ja) |
KR (1) | KR102141997B1 (ja) |
CN (1) | CN111630185A (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7392702B2 (ja) | 2021-10-28 | 2023-12-06 | トヨタ自動車株式会社 | 車両側部構造 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1711632A4 (en) | 2004-01-19 | 2009-03-11 | Technion Res & Dev Foundation | DIAGNOSTIC TEST FOR PARKINSON |
EP1907858A4 (en) | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
US8093000B2 (en) * | 2008-05-09 | 2012-01-10 | The Regents Of The University Of California | Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation |
CA2781955A1 (en) | 2009-12-01 | 2011-06-09 | Precision Therapeutics, Inc. | Multi drug response markers for breast cancer cells |
WO2012048303A2 (en) * | 2010-10-07 | 2012-04-12 | Columbia University | METHOD FOR TREATING CANCER HARBORING A p53 MUTATION |
US20140363816A1 (en) | 2011-12-22 | 2014-12-11 | The Regents Of The University Of Colorado, A Body Corporate | Methods for prediction of clinical response to radiation therapy in cancer patients |
KR101432174B1 (ko) | 2013-01-22 | 2014-08-22 | 한국원자력의학원 | Cdc27을 측정하는 제제를 포함하는 방사선 저항성 또는 민감성 진단용 조성물 및 이의 용도 |
KR20150132500A (ko) | 2013-03-15 | 2015-11-25 | 메타마크 제네틱스, 인크. | 암 예후용 조성물 및 방법 |
FR3013484B1 (fr) * | 2013-11-19 | 2018-03-23 | Idemia France | Carte a microcircuit contenant de multiples cartes predecoupees ayant une meme plage de contacts |
US10082496B2 (en) | 2014-09-10 | 2018-09-25 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
CA2968359A1 (en) | 2014-12-23 | 2016-06-30 | Genentech, Inc. | Compositions and methods for treating and diagnosing chemotherapy-resistant cancers |
WO2017104912A1 (ko) * | 2015-12-15 | 2017-06-22 | 한국원자력의학원 | 방사선 저항성 진단용 조성물 및 이의 용도 |
US11406643B2 (en) * | 2017-08-11 | 2022-08-09 | Board Of Regents, The University Of Texas System | Targeting kinases for the treatment of cancer metastasis |
-
2018
- 2018-11-20 KR KR1020180143493A patent/KR102141997B1/ko active IP Right Grant
- 2018-11-21 JP JP2020546259A patent/JP6924907B2/ja active Active
- 2018-11-21 EP EP18881259.8A patent/EP3715475A4/en active Pending
- 2018-11-21 CN CN201880087275.XA patent/CN111630185A/zh active Pending
- 2018-11-21 US US16/766,297 patent/US11674184B2/en active Active
-
2021
- 2021-07-05 JP JP2021111826A patent/JP7167263B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3715475A4 (en) | 2021-07-14 |
JP7167263B2 (ja) | 2022-11-08 |
US11674184B2 (en) | 2023-06-13 |
KR102141997B1 (ko) | 2020-08-06 |
CN111630185A (zh) | 2020-09-04 |
JP2021504726A (ja) | 2021-02-15 |
US20210025007A1 (en) | 2021-01-28 |
JP2021176852A (ja) | 2021-11-11 |
EP3715475A2 (en) | 2020-09-30 |
KR20190059237A (ko) | 2019-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20110036610A (ko) | 신규 온코진 nrf2 | |
US20130224192A1 (en) | Method for the prognosis of the progression of cancer | |
WO2013096903A2 (en) | Methods for prediction of clinical response to radiation therapy in cancer patients | |
KR101925125B1 (ko) | Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 | |
WO2015098113A1 (ja) | 悪性腫瘍の治療薬 | |
JP7167263B2 (ja) | Pmvkを有効成分として含む放射線抵抗性癌診断用または放射線治療予後予測用バイオマーカー組成物 | |
KR101315570B1 (ko) | 간암 진단 마커 및 치료제로서의 nlk | |
KR101952649B1 (ko) | Lrp-1을 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 | |
KR101943157B1 (ko) | 유방암 예후 예측용 바이오마커 | |
US10000558B2 (en) | Use of annexin A3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma | |
KR20200000969A (ko) | 췌장암 진단 또는 치료용 조성물 | |
WO2012071097A1 (en) | Methods for diagnosing and treating neuroendocrine cancer | |
KR20170052454A (ko) | 소라페닙 민감성 예측용 바이오마커 조성물 | |
WO2019103456A2 (ko) | Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물 | |
JP7012363B2 (ja) | がん患者におけるfstl1阻害剤による治療効果を予測するためのバイオマーカー | |
JP2016104716A (ja) | 膵臓癌治療用のcd95シグナル伝達阻害化合物 | |
KR101821455B1 (ko) | Awp1을 포함하는 암 전이 진단용 바이오마커 조성물 | |
US20210164982A1 (en) | Pharmaceutical use of actinin-4 involved in induction of cervical cancer | |
US20230288399A1 (en) | Method for screening colorectal cancer metastasis inhibitor | |
KR20230010414A (ko) | Csde1을 유효성분으로 포함하는 삼중음성유방암 전이 예측용 바이오마커 조성물 | |
WO2014129895A1 (en) | Means and method for increasing the sensitivity of cancers for radiotherapy | |
JP2011111435A (ja) | 神経芽腫又は膠芽腫の治療薬 | |
WO2016088818A1 (ja) | メチレンテトラヒドロ葉酸デヒドロゲナーゼ-2阻害薬に対する反応性を予測する方法 | |
GUAN et al. | LGGLGGL GGLL GGGGLGGGLGGGL GGLLG GL GLL GGGGL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210705 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210713 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210802 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6924907 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |